© 2021 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
September 30, 2021
Ophthalmologists and industry executives share what lingers on their minds at the end of the day.
September 26, 2021
Robert Weinstock, MD, discusses the efficacy and safety of intracameral dexamethasone suspension 9% compared to standard of care topical regimen for eyes receiving cataract surgery.
September 23, 2021
Cathleen McCabe, MD, shares an overview of results from a retrospective study highlighting the effectiveness of dexamethasone intraocular suspension 9% following cataract surgery.
September 21, 2021
Tibor Juhasz, CEO of ViaLase, Inc, discusses the company's development of a novel, noninvasive high-resolution OCT image-guided femtosecond laser technology for the treatment of open-angle glaucoma.
September 13, 2021
CXL is safe, effective to perform on younger population, study results show.
August 30, 2021
George O. Waring IV, MD, FACS, discusses the latest results from the GEMINI 1 clinical trial of AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia.
August 28, 2021
Steven Greenstein, MD, reports on the 10-year postop data from an epi-off corneal collagen cross-linking treatment in keratoconus and ectasia patients.
August 25, 2021
COO JD Schaub provides an overview of how RVL Pharmaceuticals has shifted toward becoming an ocular aesthetics company, with the sole purpose to fully focus on UPNEEQ®.
August 22, 2021
Michael Rivers, MD, discusses the impact of Aetna's new policy requiring prior authorization for cataract surgery on ophthalmologists, their workflow, and patients.
August 18, 2021
Michael Rivers, MD, discusses how Modernizing Medicine's latest updates to its electronic health records EMA® system benefits both ophthalmologists and optometrists.
